Brilanestrant

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBrilanestrant
Drug Alias NameARN-810RG-6046GDC-0810RO-7056118
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors degraders
TargetsEstrogen receptors
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[6
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia